Press Release

Jaguar Health Family Company Napo Pharmaceuticals to Meet with FDA to Discuss Potential Regulatory Pathways for Crofelemer for Treatment of Ultrarare Pediatric Indication Microvillus Inclusion Disease (MVID)

As announced, initial proof-of-concept results from the ongoing investigator-initiated trial in Abu Dhabi show crofelemer reduced the required total parenteral nutrition in the first participating MVID patient by up to 27%; abstract describing results accepted for presentation at upcoming North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) 2025 Annual Meeting in Chicago

Read More
Pres. Trump's Chance to Fix DEA's Marijuana Policy Failures: Rescheduling?
Press Release

Pres. Trump's Chance to Fix DEA's Marijuana Policy Failures: Rescheduling?

DEA Administrator Terrance Cole has also signaled a tough line: "Everybody knows my stance on marijuana after 30 plus years in law enforcement, so don't even ask!" However, with all due respect to law enforcement, you can't fight a disease with a badge.

MMJ is developing FDA regulated medicine, not an illicit substance. We are the science, and our mission is to treat patients, not to police a plant." Duane Boise, CEO MMJ International Holdings.

Read More